OMA Guidelines Bundle

Obesity Pharmacotherapy - Obesity Algorithm 2024

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 31 of 33

32 Supplements and Functional Foods Weight Loss Supplements Considered Potentially Unsafe by the FDA Intervention Side Effects Mechanism of Action Sibutramine b Headache, anxiety, dry mouth, insomnia, myocardial infarction and stroke Monoamine reuptake inhibitor, increasing norepinephrine, serotonin and dopamine concentrations in the synaptic clefts and suppressing hunger. Sibutramine was removed f rom the market as an anti-obesity pharmaceutical in 2010. a Potentially unsafe when synephrine content is higher than recommended daily limits and when combined with caffeine or unsafe and undeclared synthetic ingredients. b Some herbal "weight loss pills" are banned by the FDA due to sibutramine as an active component. e results of a clinical trial demonstrated prescription sibutramine increased myocardial infarction and stroke. Despite FDA warnings of the dangers of sibutramine, sibutramine can still be found as a "hidden ingredient" in weight loss supplements. (cont'd)

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - Obesity Algorithm 2024